Top Markets
Coin of the day
Grace Therapeutics, Inc. Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCE
Clasificación en acciones #27036
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Precio por acción
$2.18
Última sincronización: 2026-08-19
Capitalización bursátil
$35.55M
Cambio (1 día)
2.57%
Cambio (1 año)
-33.19%
País
US
Comercio Grace Therapeutics, Inc. (GRCE)

Categoría

Ganancias de Grace Therapeutics, Inc. (GRCE)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Grace Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Grace Therapeutics, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$-3.09B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH